Hubei Huaqiang High-Tech Co., Ltd. Class A

Hubei Huaqiang High-Tech Co., Ltd. Class A

SSSE:688151
17.41
CNY
+0.61
(+3.63%)
0.15EPS
101.68P/E
5.12BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.41
3.1
6.84
3.46
4.95
1.72
1.45
1.9
1.76
2.03
Basic EPS, GAAP
0.24
0.43
0.54
0.73
1.24
0.2
0.02
0.07
0.12
0.15
Free Cash Flow per Basic Share
0.72
0.36
1.22
-1.81
1.67
-0.66
-0.31
-0.57
0.02
- -
Dividend per Share
0.11
0.01
0.11
0.11
0.25
0.34
0.07
0.03
0.14
- -
Book Value per Share
2.92
3.23
3.68
4.48
12.29
12.15
12.11
12.19
12.27
12.24
Tangible Book Value per Share
2.41
2.83
3.29
4.11
12.02
11.9
11.86
11.96
12.05
12.02
Basic Weighted Avg Shares
243
240
241
241
257
340
396
322
356
343
Sales/Revenue/Turnover
585
743
1,648
835
1,275
586
573
611
628
695
Operating Margin (%)
13.96
10.37
10.39
15.16
31.28
-1.63
-7.33
-7.06
1.82
3.91
Depreciation Expense
19
27
36
88
57
55
57
59
55
- -
Net Income, GAAP
58
103
130
176
319
68
8
23
43
50
Effective Tax Rate (%)
11.89
18.83
17.96
17.48
12.92
- -
- -
- -
6.03
7.56
Profit Margin (%)
9.94
13.88
7.9
21.1
25.04
11.62
1.38
3.68
6.81
7.22
Working Capital
471
579
714
856
3,887
3,789
3,312
3,165
3,605
3,717
LT Debt
- -
- -
- -
- -
- -
- -
2
- -
- -
- -
Total Equity
754
835
950
1,158
4,233
4,187
4,170
4,200
4,228
4,218
Return on Invested Capital (%)
- -
12.51
13.78
16.35
11.84
- -
- -
- -
1.09
1.21
Return on Capital (%)
- -
12.47
14.04
16.32
11.81
- -
- -
- -
1.02
1.19
Return on Common Equity (%)
- -
12.99
14.57
16.72
11.84
1.62
0.19
0.54
1.02
1.19

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
345
345
345
Market Capitalization
7,104
7,172
5,123

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,903
3,858
3,987
Cash, Cash Equivalents & STI
2,518
2,495
2,494
Accounts Receivable, Net
608
601
618
Inventories
157
138
141
Total Current Liabilities
298
259
271
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
53.08%
0.66%
Free Cash Flow
- -
-90.46%
-103.09%
Net Income, GAAP
- -
37.65%
89.89%
Sales/Revenue/Turnover
- -
1.18%
2.78%
Total Cash Common Dividend
- -
115.3%
499.39%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
121
119
102
269
611
2025
65
113
- -
363
628
2026
104
115
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
- -
-0.01
0.07
2025
0.01
0.01
- -
0.11
0.12
2026
0.02
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.02
0.03
2025
- -
- -
- -
- -
0.14
2026
- -
- -
- -
- -
- -

Company Description

CEO
Bang Lao Liu
Full Time Employees
635
Sector
Producer manufacturing
Industry
Miscellaneous manufacturing
Address
Yichang China
IPO Date
Dec 6, 2021
Business
Hubei Huaqiang High-Tech Co., Ltd. is a China-based manufacturing enterprise primarily engaged in the research, development, production, and sale of pharmaceutical packaging materials, medical devices, and special chemical, biological, radiological, and nuclear (CBRN) protective equipment. Founded in 2001 and headquartered in Yichang, Hubei Province, the company operates as a key specialized industrial subsidiary under China South Industries Group Corporation (CSGC), serving clients across defense, clinical healthcare, and commercial pharmaceutical sectors both domestically and internationally. The company operates through three principal business segments: Pharmaceutical Packaging Materials, Medical Devices, and Special Protective Equipment. Its Pharmaceutical Packaging Materials portfolio comprises halobutyl medicinal rubber stoppers for freeze-dried formulations, sterile powder injections, large-volume parenterals, and vacuum blood collection tubes; high-compatibility film-coated rubber stoppers; multi-layer co-extruded infusion films; and aluminum-plastic combination closure seals. The Medical Devices segment manufactures surgical and particulate protective masks; disposable medical protective coveralls; rubber plungers and tip caps for pre-filled syringes; and precision drug delivery assemblies. The Special Protective Equipment segment develops and supplies individual protective systems, including military and industrial gas masks, breathable chemical protective suits, protective hoods, and specialized protective boots; as well as collective filtration systems, including high-efficiency filter absorbers, air purification ventilation units, and integrated protective installations for civil defense and specialized defense facilities. In recent developments, Hubei Huaqiang High-Tech Co., Ltd. has expanded its operational footprint through the phased commissioning of its New Drug Delivery Devices and Packaging Materials R&D and Industrialization Project, constructing automated, cleanroom-compliant production lines to increase manufacturing capacity for high-barrier coated stoppers and prefillable syringe components. The company has integrated automated vulcanization robotics, robotic trimming systems, and automated optical inspection equipment developed in collaboration with the Institute of Automation of the Chinese Academy of Sciences to accelerate intelligent manufacturing across its packaging operations. Furthermore, the company has established a Public Service Platform for Pharmaceutical Excipients and Packaging Materials Testing and Evaluation to deliver technical validation and regulatory compliance services. Strategically, the company has expanded commercial supply agreements with major pharmaceutical enterprises, including Sinopharm, Guangzhou Pharmaceutical Holdings, Hisun Pharmaceutical, and Luye Pharma, focusing product development on high-end container closure solutions for biopharmaceuticals and advanced injectable therapeutics.